KR20240112929A - Ccr8 항원 결합 단위 및 그들의 용도 - Google Patents
Ccr8 항원 결합 단위 및 그들의 용도 Download PDFInfo
- Publication number
- KR20240112929A KR20240112929A KR1020247021902A KR20247021902A KR20240112929A KR 20240112929 A KR20240112929 A KR 20240112929A KR 1020247021902 A KR1020247021902 A KR 1020247021902A KR 20247021902 A KR20247021902 A KR 20247021902A KR 20240112929 A KR20240112929 A KR 20240112929A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- binding unit
- cells
- antigen
- antigen binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/134930 | 2021-12-02 | ||
| CN2021134930 | 2021-12-02 | ||
| PCT/CN2022/136276 WO2023098888A1 (en) | 2021-12-02 | 2022-12-02 | Ccr8 antigen binding unit and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240112929A true KR20240112929A (ko) | 2024-07-19 |
Family
ID=86611552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247021902A Pending KR20240112929A (ko) | 2021-12-02 | 2022-12-02 | Ccr8 항원 결합 단위 및 그들의 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250034266A1 (https=) |
| EP (1) | EP4441098A4 (https=) |
| JP (1) | JP2024541680A (https=) |
| KR (1) | KR20240112929A (https=) |
| CN (1) | CN119072494A (https=) |
| AU (1) | AU2022400921A1 (https=) |
| CA (1) | CA3239784A1 (https=) |
| IL (1) | IL313177A (https=) |
| MX (1) | MX2024006743A (https=) |
| TW (1) | TW202342533A (https=) |
| WO (1) | WO2023098888A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4661869A1 (en) | 2023-02-06 | 2025-12-17 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators |
| WO2024240224A1 (zh) * | 2023-05-23 | 2024-11-28 | 再鼎医药(上海)有限公司 | 包含抗ccr8抗体的制剂及其用途 |
| JPWO2024248037A1 (https=) | 2023-05-30 | 2024-12-05 | ||
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| CN120230205A (zh) * | 2023-12-29 | 2025-07-01 | 苏州泽璟生物制药股份有限公司 | 包含ccr8抗原结合结构域的多特异性抗体 |
| WO2025186043A1 (en) | 2024-03-06 | 2025-09-12 | Bayer Aktiengesellschaft | Pharmaceutical formulation for anti-ccr8 antibodies |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| US10087259B1 (en) * | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| CN110835371A (zh) * | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8单克隆抗体及其应用 |
| WO2020138489A1 (ja) * | 2018-12-27 | 2020-07-02 | 塩野義製薬株式会社 | 新規抗ｃｃｒ８抗体 |
| TWI890283B (zh) * | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| AU2021244200A1 (en) * | 2020-03-23 | 2022-11-24 | Bristol-Myers Squibb Company | Anti-CCR8 antibodies for treating cancer |
| TW202216771A (zh) * | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
-
2022
- 2022-12-02 US US18/715,739 patent/US20250034266A1/en active Pending
- 2022-12-02 CA CA3239784A patent/CA3239784A1/en active Pending
- 2022-12-02 KR KR1020247021902A patent/KR20240112929A/ko active Pending
- 2022-12-02 WO PCT/CN2022/136276 patent/WO2023098888A1/en not_active Ceased
- 2022-12-02 CN CN202280080188.8A patent/CN119072494A/zh active Pending
- 2022-12-02 IL IL313177A patent/IL313177A/en unknown
- 2022-12-02 AU AU2022400921A patent/AU2022400921A1/en active Pending
- 2022-12-02 MX MX2024006743A patent/MX2024006743A/es unknown
- 2022-12-02 TW TW111146368A patent/TW202342533A/zh unknown
- 2022-12-02 EP EP22900692.9A patent/EP4441098A4/en active Pending
- 2022-12-02 JP JP2024533211A patent/JP2024541680A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022400921A1 (en) | 2024-06-27 |
| CA3239784A1 (en) | 2023-06-08 |
| EP4441098A4 (en) | 2026-03-04 |
| JP2024541680A (ja) | 2024-11-08 |
| MX2024006743A (es) | 2024-08-27 |
| EP4441098A1 (en) | 2024-10-09 |
| TW202342533A (zh) | 2023-11-01 |
| WO2023098888A1 (en) | 2023-06-08 |
| US20250034266A1 (en) | 2025-01-30 |
| IL313177A (en) | 2024-07-01 |
| CN119072494A (zh) | 2024-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102607101B1 (ko) | Cd47 항원 결합 유닛 및 그것의 사용 | |
| KR20240112929A (ko) | Ccr8 항원 결합 단위 및 그들의 용도 | |
| EP3504240B1 (en) | Anti-tim-3 antibodies | |
| JP2020504171A (ja) | 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP2020504095A (ja) | 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP2019512230A (ja) | Ｇｉｔｒ抗体、方法、及び使用 | |
| US20220119546A1 (en) | Plectin-1 binding antibodies and uses thereof | |
| EP3404040B1 (en) | Anti-myl9 antibody | |
| AU2011327208B2 (en) | Anti single-strand type-IV collagen polypeptide antibody, and pharmaceutical, or agent for diagnosing, preventing or treating tumours, containing same | |
| US20220127364A1 (en) | Novel anti-pd-l1 antibody and uses thereof | |
| HK40120943A (zh) | Ccr8抗原结合单元及其用途 | |
| RU2780859C2 (ru) | Cd47-антигенсвязывающая единица и ее применение | |
| CA3253998A1 (en) | ANTIBODIES DIRECTED AGAINST LYPD3 | |
| HK40015810A (en) | Cd47 antigen binding unit and uses thereof | |
| HK40003023B (en) | Anti-tim-3 antibodies | |
| NZ749820B2 (en) | Anti-tim-3 antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20240701 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application |